Biology of Blood and Marrow Transplantation
Volume 10, Issue 4 , Pages 276-282 , April 2004

A randomized trial of amifostine and carmustine-containing chemotherapy to assess lung-protective effects

  • Roy B Jones

      Affiliations

    • M.D. Anderson Cancer Center, Houston, Texas, USA
    • Corresponding Author InformationCorrespondence and reprint requests: Roy B. Jones, MD, PhD, Department of Blood and Marrow Transplantation, M.D. Anderson Cancer Center, 1515 Holcombe Blvd. 423, Houston, TX 77030 USA
    • ,
  • Keith E Stockerl-Goldstein

      Affiliations

    • Stanford University Medical Center, Palo Alto, California, USA
    • ,
  • Jared Klein

      Affiliations

    • Karmanos Cancer Center, Detroit, Michigan, USA
    • ,
  • James Murphy

      Affiliations

    • National Jewish Medical and Research Center, Denver, Colorado, USA
    • ,
  • Karl G Blume

      Affiliations

    • Stanford University Medical Center, Palo Alto, California, USA
    • ,
  • Roger Dansey

      Affiliations

    • Karmanos Cancer Center, Detroit, Michigan, USA
    • ,
  • Charles Martinez

      Affiliations

    • M.D. Anderson Cancer Center, Houston, Texas, USA
    • ,
  • Steven Matthes

      Affiliations

    • M.D. Anderson Cancer Center, Houston, Texas, USA
    • ,
  • Yago Nieto

      Affiliations

    • University of Colorado Health Sciences Center, Denver, Colorado, USA

Received 11 November 2003 ,Accepted 21 January 2004.

References 

  1. Capizzi R. Amifostine (the preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies). Semin Oncol. 1996;23(4 suppl 8):2–17
  2. Kemp G, Rose P, Berman M, et al.  Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities (results of a randomized control trial in patients with advanced ovarian cancer). J Clin Oncol. 1996;14:2101–2112
  3. Buntzel J, Schuth J, Kuttner K, Glatzel M. Radiochemotherapy with amifostine cytoprotection for head and neck cancer. Support Care Cancer. 1998;6:155–160
  4. Phillips GL. The potential of amifostine in high-dose chemotherapy and autologous hematopoietic stem cell transplantation. Semin Oncol. 2002;29(6 suppl 19):53–56
  5. Mollman JE, Glover DJ, Hogan WM, et al.  Cisplatin neurotoxicity. Risk factors, prognosis, and protection by WR-2721. Cancer. 1988;61:2192–2195
  6. Tannehill SP, Mehta MP, Larson M, et al.  Effect of amifostine on toxicities associated with sequential chemotherapy and radiation therapy for unresectable non-small-cell lung cancer (results of a phase II trial). J Clin Oncol. 1997;15:2850–2857
  7. Capizzi RL. The preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies by amifostine. Semin Oncol. 1999;26(2 suppl 7):3–21
  8. Capizzi RL, Oster W. Chemoprotective and radioprotective effects of amifostine (an update of clinical trials). Int J Hematol. 2000;72:425–435
  9. Cao TM, Negrin RS, Stockerl-Goldstein K, et al.  Pulmonary toxicity syndrome in breast cancer patients undergoing BCNU-containing high-dose chemotherapy and autologous hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2000;6:387–394
  10. Jones RB, Matthes S, Shpall EJ, et al.  Acute lung injury following treatment with high-dose cyclophosphamide, cisplatin, and carmustine (pharmacodynamic evaluation of carmustine). J Natl Cancer Inst. 1993;85:640–647
  11. Wilczynski SW, Erasmus JJ, Petros WP, Vredenburgh JJ, Folz RJ. Delayed pulmonary toxicity syndrome following high-dose chemotherapy and bone marrow transplantation for breast cancer. Am J Respir Crit Care Med. 1998;157:565–573
  12. Chap L, Shpiner R, Levine M, Norton L, Lill M, Glaspy J. Pulmonary toxicity of high-dose chemotherapy for breast cancer (a non-invasive approach to diagnosis and treatment). Bone Marrow Transplant. 1997;20:1063–1067
  13. Rubio C, Hill ME, Milan S, O’Brien ME, Cunningham D. Idiopathic pneumonia syndrome after high-dose chemotherapy for relapsed Hodgkin’s disease. Br J Cancer. 1997;75:1044–1048
  14. Peters WP, Shpall EJ, Jones RB, et al.  High-dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer. J Clin Oncol. 1988;6:1368–1376
  15. Jones RB, Matthes S, Shpall EJ, et al.  BCNU pharmacokinetics in 72 patients treated with high-dose combination chemotherapy and autologous bone marrow support. Analytical methodology and patient data. J Chromatogr Biomed. 1994;
  16. Peters WP, Rosner G, Vredenburgh J, et al.  A prospective, randomized comparison of two doses of combination alkylating agents (AA) as consolidation after CAF in high-risk primary breast cancer involving ten or more axillary lymph nodes (LN) (preliminary results of CALGB 9082/SWOG 9114/NCIC MA-13). Proc Am Soc Clin Oncol. 1999;18:1a; [meeting abstract]
  17. Zander AR, Culbert S, Jagannath S, et al.  High-dose cyclophosphamide, BCNU, and VP-16 (CBV) as a conditioning regimen for allogeneic bone marrow transplantation for patients with acute leukemia. Cancer. 1987;59:1083–1096
  18. Chopra R, McMillan AK, Linch DC, et al.  The place of high-dose BEAM therapy and autologous bone marrow transplantation in poor-risk Hodgkin’s disease. A single-center eight-year study of 155 patients. Blood. 1993;81:1137–1145
  19. Alberts DS, Speicher LA, Krutzsch M, et al.  WR-1065, the active metabolite of amifostine (Ethyol), does not inhibit the cytotoxic effects of a broad range of standard anticancer drugs against human ovarian and breast cancer cells. Eur J Cancer. 1996;32A(suppl 4):S17–S20
  20. Wasserman TH, Phillips TL, Ross G, Kane L. Differential protection against chemotherapeutic effects on bone marrow CFUs by WR-2721. Cancer Clin Trials. 1981;4:3–6
  21. Becker K, Schirmer RH. 1,3-Bis(2-chloroethyl)-1-nitrosourea as thiol-carbamoylating agent in biological systems. Methods Enzymol. 1995;251:173–188
  22. Davis MR, Kassahun K, Jochheim CM, Brandt KM, Baillie TA. Glutathione and N-acetylcysteine conjugates of 2-chloroethyl isocyanate. Identification as metabolites of N,N′-bis(2-chloroethyl)-N-nitrosourea in the rat and inhibitory properties toward glutathione reductase in vitro. Chem Res Toxicol. 1993;6:376–383
  23. Sriramachari S, Jeevaratnam K. Comparative toxicity of methyl isocyanate and its hydrolytic derivatives in rats. Arch Toxicol. 1994;69:45–51
  24. Durant JR, Norgard NJ, Murad TM, Bartolucci AA, Langford KH. Pulmonary toxicity associated with bischloroethylnitrosourea (BCNU). Ann Intern Med. 1979;90:191–194
  25. Seiden MV, Elias A, Ayash L, et al.  Pulmonary toxicity associated with high dose chemotherapy in the treatment of solid tumors with autologous marrow transplant (an analysis of four chemotherapy regimens). Bone Marrow Transplant. 1992;10:57–63
  26. Todd NW, Peters WP, Ost AH, Roggli VL, Piantadosi CA. Pulmonary drug toxicity in patients with primary breast cancer treated with high-dose combination chemotherapy and autologous bone marrow transplantation. Am Rev Respir Dis. 1993;147:1264–1270
  27. Jones RB, Matthes S, Shpall EJ, et al.  Acute lung injury following high-dose cyclophosphamide, cisplatin and BCNU. Pharmacodynamic evaluation of BCNU. J Natl Cancer Inst. 1993;85:640–647

PII: S1083-8791(04)00046-1

doi: 10.1016/j.bbmt.2004.01.001

Biology of Blood and Marrow Transplantation
Volume 10, Issue 4 , Pages 276-282 , April 2004

Article Tools

* Image Usage & Resolution